source
- Neurosterix raises $105M Series B to advance oral M4 schizophrenia drug and adds former Karuna leadersNeurosterix, a spinout from Addex Therapeutics, announced a $105 million Series B financing. The round was led by RTW Investments with participation from GV, Janus Henderson Investors and others. A…
- Pfizer secures up to $1.5 billion from Blackstone to fund berobenatide obesity drug developmentPfizer announced a financing arrangement with Blackstone Life Sciences that could provide up to $1.5 billion to support the development of berobenatide, an obesity drug acquired from Metsera. The…